Lv53
960 积分 2022-08-19 加入
Towards the Development of a Commercial Process To Produce Muvalaplin. Part I: Preparation of a Key Intermediate by an Evans Auxiliary-Assisted Asymmetric Alkylation
9分钟前
待确认
Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor
29天前
已完结
Abstract 6177: ATRN-119 and ATRN-W1051: Novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment
1个月前
已关闭
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers
1个月前
已完结
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
1个月前
已完结
Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344
1个月前
已完结
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)
1个月前
已完结
Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody–drug conjugates
1个月前
已完结
The Discovery and Process Chemistry Development of GDC-0084, a Brain Penetrating Inhibitor of PI3K and mTOR
1个月前
已完结
Enzymatic Prenylation and Oxime Ligation for the Synthesis of Stable and Homogeneous Protein–Drug Conjugates for Targeted Therapy
1个月前
已完结
皖公网安备34019202002308
